Autosomal dominant polycystic kidney disease: Role of the renin-angiotensin system in raised blood pressure in progression of renal and cardiovascular disease

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 7, Issue 3, 2006, Pages 139-145

  Lawson, Catherine R ^a   Doulton, Timothy W ^a   MacGregor, Graham A ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

ACE inhibitor; Autosomal dominant polycystic kidney disease; Blood pressure; Renin angiotensin system; Sodium

Indexed keywords

ALDOSTERONE; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ATENOLOL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; RENIN; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOPRESSIN RECEPTOR ANTAGONIST;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; DISEASE COURSE; DRUG MECHANISM; DRUG RESPONSE; ESSENTIAL HYPERTENSION; HUMAN; HYPERTENSION; KIDNEY ISCHEMIA; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; KIDNEY VASCULAR RESISTANCE; NATRIURESIS; NONHUMAN; PATHOGENESIS; PLASMA RENIN ACTIVITY; PREVALENCE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SODIUM INTAKE; SODIUM RETENTION; SYMPATHETIC TONE; WATER RETENTION;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DISEASE PROGRESSION; HUMANS; HYPERTENSION, RENAL; KIDNEY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENIN-ANGIOTENSIN SYSTEM; SYMPATHETIC NERVOUS SYSTEM; VASCULAR RESISTANCE;

EID: 33750976192     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.3317/jraas.2006.023     Document Type: Review

References (74)

1. Ansell D, Feest T, Ahmad A, Rao R. UK Renal Registry: 7th Annual Report: UK Renal Registry, 2004.
2. Somlo S, Saggar-Malik AK. Autosomal dominant polycystic kidney disease. In: Flinter F, Maher E, Saggar-Malik AK, editors. The Genetics of Renal Disease. Oxford, 2003:204-27.
3. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 2002;13:2384-98.
4. Ong AC, Harris PC. Molecular pathogenesis of ADPKD: the polycystin complex gets complex. Kidney Int 2005;67:1234-47.
5. Wilson P. Polycystic kidney disease. N Engl J Med 2004;350:151-64.
6. Peters DJ, Spruit L, Saris JJ et al. Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 1993;5:359-62.
7. Hateboer N, van Dijk MA, Bogdanova N et al. Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group. Lancet 1999;353:103-07.
8. Chapman AB, Gabow PA. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int Suppl 1997;61:S71-S73.
9. Calabrese G, Vagelli G, Cristofano C, Barsotti G. Behaviour of arterial pressure in different stages of polycystic kidney disease. Nephron 1982;32:207-08.
10. Gabow PA, Ikle DW, Holmes JH. Polycystic kidney disease: prospective analysis of nonazotemic patients and their family members. Ann Intern Med 1984;101:238-47.
11. Gabow PA. Autosomal dominant polycystic kidney disease - more than just a renal disease. Am J Kidney Dis 1990;16:403-13.
12. Hansson L, Karlander LE, Lundgren W, Peterson LE. Hypertension in polycystic kidney disease. Scand J Urol Nephrol 1974;8:203-05.
13. Milutinovic J, Fialkow PJ, Agodoa LY, Phillips LA, Rudd TG, Sutherland S. Clinical manifestations of autosomal dominant polycystic kidney disease in patients older than 50 years. Am J Kidney Dis 1990;15:237-43.
14. Gabow PA, Johnson AM, Kaehny WD et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int 1992;41:1311-19.
15. Fick GM, Johnson AM, Hammond WS, Gabow PA. Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2048-56.
16. Franz KA, Reubi FC. Rate of functional deterioration in polycystic kidney disease. Kidney Int 1983;23:526-9.
17. Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis 2002;39:1127-34.
18. Gabow PA, Chapman AB, Johnson AM et al. Renal structure and hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1990;38:1177-80.
19. Gabow PA, Heard E, Pertorius D et al. Relationship between renal structure and hypertension in autosomal dominant polycystic kidney disease (ADPKD). Kidney Int 1995;31:297.
20. Ritter SA, Baehr G. The arterial supply of the congenital polycystic kidney and its relation to the clinical picture. J Urol 1929;21:583-92.
21. Ettinger A, Kahn PC, Wise HMJ. The importance of selective renal angiography in the diagnosis of polycystic disease. J Urol 1969;102:156-61.
22. Nash DAJ. Hypertension in polycystic kidney disease without renal failure. Arch Int Med 1977;137:1571-5.
23. Valvo E, Gammaro L, Tessitore N et al. Hypertension of polycystic kidney disease: mechanisms and hemodynamic alterations. Am J Nephrol 1985;5:176-81.
24. Torres VE, Wilson DM, Burnett JC, Johnson CM, Offord KP. Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. Mayo Clin Proc 1991;66:1010-17.
25. Bell PE, Hossack KF, Gabow PA, Durr JA, Johnson AM, Schrier RW. Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1988;34:683-90.
26. Ramunni A, Saracino A, Esposito T, Saliani MT, Coratelli P. Renal vascular resistance and renin-angiotensin system in the pathogenesis of early hypertension in autosomal dominant polycystic kidney disease. Hypertens Res 2004;27:221-5.
27. Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990;323:1091-6.
28. Cappuccio FP, Markandu ND, Sagnella GA, MacGregor GA. Sodium restriction lowers high blood pressure through a decreased response of the renin system - direct evidence using saralasin. J Hypertens 1985;3:243-7.
29. MacGregor GA, Markandu ND, Roulston JE, Jones JC, Morton JJ. The renin-angiotensin-aldosterone system in the maintenance of blood pressure, aldosterone secretion and sodium balance in normotensive subjects. Clin Sci 1980;59:95s-99s.
30. Sagnella GA. Why is plasma renin activity lower in populations of African origin? J Hum Hypertens 2001;15:17-25.
31. Doulton TWR, Saggar-Malik AK, He FJ et al. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating renin-angiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens 2006;24(5):939-45.
32. Martinez-Vea A, Valero FA, Bardaji A et al. Left ventricular hypertrophy in hypertensive patients with autosomal dominant polycystic kidney disease: Influence of blood pressure and humoral and neurohormonal factors. Am J Nephrol 2000;20:193-200.
33. Watson ML, MacNicol AM, Allan PL, Wright AF. Effects of angiotensin converting enzyme inhibition in adult polycystic kidney disease. Kidney Int 1992;41:206-10.
34. Barrett BJ, Foley R, Morgan J, Hefferton D, Parfrey P. Differences in hormonal and renal vascular responses between normotensive patients with autosomal dominant polycystic kidney disease and unaffected family members. Kidney Int 1994;46:1118-23.
35. Harrap SB, Davies DL, Macnicol AM et al. Renal, cardiovascular and hormonal characteristics of young adults with autosomal dominant polycystic kidney disease. Kidney Int 1991;40:501-08.
36. Graham PC, Lindop GBM. The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int 1988;33:1084-90.
37. Torres VE, Donovan KA, Scicli G et al. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int 1992;42:364-73.
38. Loghman-Adham M, Soto C, Inagami T, Cassis L. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2004;287:F775-F788.
39. McPherson EA, Luo Z, Brown RA et al. Chymase-like angiotensin II-generating activity in end-stage human autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2004;15:493-500.
40. Lavoie JL, Lake-Bruse KD, Sigmund CD. Increased blood pressure in transgenic mice expressing both human renin and angiotensinogen in the renal proximal tubule. Am J Physiol Renal Physiol 2004;286:F965-F971.
41. Crowley SD, Gurley SB, Oliverio MI et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest 2005;115(4):1092-9.
42. de Leeuw PW, Birkenhager WH. The renal circulation in essential hypertension. J Hypertens 1983;1:321-31.
43. Lightenberg G, Blankestijn PJ, Oey PL et al. Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure. N Engl J Med 1999;340:1321-8.
44. Tuncel M, Augustyniak R, Zhang W, Toto RD, Victor RG. Sympathetic nervous system function in renal hypertension. Curr Hypertens Reports 2002;4:229-36.
45. Neumann J, Ligtenberg G, Klein II, Koomans HA, Blankestijn PJ. Sympathetic hyperactivity in chronic kidney disease: Pathogenesis, clinical relevance and treatment. Kidney Int 2004;65:1568-76.
46. Klein IHHT, Ligtenberg G, Oey PL, Koomans HA, Blankestijn PJ. Sympathetic activity is increased in polycystic kidney disease and is associated with hypertension. J Am Soc Nephrol 2001;12:2427-33.
47. Wang D, Strandgaard S. The pathogenesis of hypertension in autosomal dominant polycystic kidney disease. J Hypertens 1997;15:925-33.
48. Schmid M, Mann JF, Stein G et al. Natriuresis-pressure relationship in polycystic kidney disease. J Hypertens 1990;8:277-83.
49. Torres VE, Wilson DM, Offord KP, Burnett JC, Romero JC. Natriuretic response to volume expansion in polycystic kidney disease. Mayo Clin Proc 1989;64:509-15.
50. Danielsen H, Pedersen EB, Nielsen AH, Herlevsen P, Komerup HJ, Posborg V. Expansion of extracellular volume in early polycystic kidney disease. Acta Med Scand 1986;219:399-405.
51. Zabka J, Tesar V, Merta M. Hypertension in patients with polycystic kidney disease [abstract]. Sbornik Lebarsky 1991;93:325-38.
52. Haroun MK, Jaar BG, Hoffman SC, Comstock GW, Klag MJ, Coresh J. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003;14:2934-41.
53. Klag MJ, Whelton PK, Randall BL et al. Blood pressure and end-stage renal disease in men. N Engl J Med 1996;334:13-18.
54. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, Group ftCS. The effect of angiotensin-converting enzyme inhbition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
55. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy in type 2 diabetes. N Engl J Med 2001;45:851-60.
56. Brenner BM, Cooper ME, De Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-9.
57. Ecder T, Edelstein CL, Fick-Brosnahan GM et al. Diuretics versus angiotensin-converting enzyme inhibitors in autosomal dominant polycystic kidney disease. Am J Nephrol 2001;21:98-103.
58. Schrier RW, McFann K, Johnson A et al. Cardiac and renal effects of standard versus rigourous blood pressure control in autosomal-dominant polycystic kidney disease: Results of a seven-year prospective randomized study. J Am Soc Nephrol 2002;13:1733-9.
59. van Dijk MA, Breuning MH, Duiser R, vas Es LA, Westendorp RGJ. No effect of enalapril on progression in ADPKD. Nephrol Dial Transplant 2003;18:2314-20.
60. Jafar TH, Stark PC, Schmid CH et al. The effect of angiotensin-converting enzyme inhibitors on progression of advanced polycystic kidney disease. Kidney Int 2005;67:265-71.
61. Florijn KW, Chang PC, van der Woude FJ, van Bockel J, van Saase JL. Long-term cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease patients after renal transplantation. Transplantation 1994;57(1):73-81.
62. De Simone G. Left ventricular geometry and hypotension in end-stage renal disease: A mechanical perspective. J Am Soc Nephrol 2003;14:2421-7.
63. Kannel WB. Left ventricular hypertrophy as a risk factor: the Framingham experience. J Hypertens Suppl 1991;9(2):S3-S8.
64. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991;114:345-52.
65. Chapman AB, Johnson AM, Rainguet S, Hossack KF, Gabow PA, Schrier RW. Left ventricular hypertrophy in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1997;8:1292-7.
66. Ivy DD, Shaffer EM, Johnson AM, Kimberling WJ, Gabow PA. Cardiovascular abnormalities in children with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1995;5:2032-6.
67. Valero FA, Martinez-Vea A, Bardaji A et al. Ambulatory blood pressure and left ventricular mass in normotensive patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1999;10:1020-6.
68. Saggar-Malik AK, Missouris CG, Gill JS, Singer DRJ, Markandu ND, MacGregor GA. Left ventricular mass in normotensive subjects with autosomal dominant polycystic kidney disease. Br Med J 1994;309:1617-18.
69. Zeier M, Geberth S, Schmidt KG, Mandelbaum A, Ritz E. Elevated blood pressure profile and left ventricular mass in children and young adults with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 1993;3:1451-7.
70. Ecder T, Edelstein CL, Chapman A et al. Reversal of left ventricular hypertrophy with angiotensin converting enzyme inhibition in hypertensive patients with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 1999;14:1113-16.
71. Tao Y, Kim J, Schrier RW, Edelstein CL. Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 2005;16:46-51.
72. Shillingford JM, Murcia NS, Larson CH et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci USA 2006;103:5466-71.
73. Mangoo-Karim R, Uchic ME, Grant M et al. Renal epithelial fluid secretion and cyst growth: the role of cyclic AMP. FASEB Journal 1989;3:2629-32.
74. Walz G. Therapeutic approaches in autosomal dominant polycystic kidney disease (ADPKD): is there light at the end of the tunnel? Nephrol Dial Transplant 2006;21:1752-7.